🇺🇸 FDA
Pipeline program

EPI-321

EPI-321-02

Phase 2 mab active

Quick answer

EPI-321 for Facioscapulohumeral Muscular Dystrophy is a Phase 2 program (mab) at Biotech Pharmaceutical Co., with 1 ClinicalTrials.gov record(s).

Program details

Company
Biotech Pharmaceutical Co.,
Indication
Facioscapulohumeral Muscular Dystrophy
Phase
Phase 2
Modality
mab
Status
active

Clinical trials